SLC5A2 and type 2 diabetes mellitus: Zelniker Zelniker TA TA Wiviott Wiviott SD SD Raz Raz I I SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials Lancet Lancet 2018 2018 292 292 31 31 39 39